RxDoctor Payments Data

Paul Chung, MD

Internal Medicine · Dallas, TXNPI 1427165992

Payments from drug & device makers

$1,045in general payments, 2019–2025

Across 63 payments — averaging $16.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$338
  • GSK$267
  • AbbVie$117
  • Siemens Medical Solutions USA, Inc.$57
  • Lilly USA, LLC$56
  • Amgen$45
  • plus $165 from 8 others

What the payments were for

  • Food & beverage$1,045100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,045 in reported general payments places this provider in the 65th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$188,707
Medicare patients
247
Services billed
5,490

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide100$151,437
MounjaroTirzepatide139$149,874
JardianceEmpagliflozin70$96,851
EliquisApixaban69$55,170
TrulicityDulaglutide31$50,793
AptiomEslicarbazepine Acetate13$30,251
Trelegy ElliptaFluticasone/Umeclidin/Vilanter25$27,981
FarxigaDapagliflozin Propanediol20$21,279
JanuviaSitagliptin Phosphate13$18,028
XareltoRivaroxaban20$15,446
RybelsusSemaglutide14$13,386
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog14$10,885
Breo ElliptaFluticasone/Vilanterol14$6,883
Atorvastatin Calcium487$5,244
PremarinEstrogens, Conjugated15$4,635

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$56$200,667170 claims
Novo NordiskOzempic, Rybelsus$338$164,823114 claims
GSKTrelegy Ellipta, Breo Ellipta$267$34,86439 claims
Johnson & JohnsonXarelto$23$15,44620 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →